Neoadjuvant chemoradiotherapy in patients with unresectable locally advanced sigmoid colon cancer: clinical feasibility and outcome

Autor: Li Ren Li, Yan Yuan, Qiao Xuan Wang, Xiaojun Wu, Zhen Hai Lu, Shao Qing Niu, Wei Wei Xiao, Zhi Fan Zeng, Pei-Rong Ding, Rong Zhen Li, Wei Hao Xie, Yuanhong Gao, Hui Chang
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
medicine.medical_treatment
R895-920
Medical physics. Medical radiology. Nuclear medicine
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Sigmoid colon cancer
RC254-282
Colectomy
Down staging
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Radiotherapy Dosage
Chemoradiotherapy
Middle Aged
Neoadjuvant Therapy
Progression-Free Survival
Neoadjuvant chemoradiotherapy
Survival Rate
Oncology
030220 oncology & carcinogenesis
Lymphatic Metastasis
030211 gastroenterology & hepatology
Female
medicine.drug
Adult
medicine.medical_specialty
Organ preservation
Capecitabine
03 medical and health sciences
medicine
Humans
Radiology
Nuclear Medicine and imaging
Aged
Retrospective Studies
Chemotherapy
Pathological complete response
Lymphatic Irradiation
business.industry
Research
Retrospective cohort study
medicine.disease
Surgery
Lymphoma
Radiation therapy
Regimen
Sigmoid Neoplasms
Radiotherapy
Intensity-Modulated
business
Organ Sparing Treatments
Zdroj: Radiation Oncology (London, England)
Radiation Oncology, Vol 16, Iss 1, Pp 1-9 (2021)
ISSN: 1748-717X
Popis: Background Patients with locally advanced sigmoid colon cancer (LASCC) have limited treatment options and a dismal prognosis with poor quality of life. This retrospective study aimed to further evaluate the feasibility and efficacy of neoadjuvant chemoradiotherapy (NACRT) followed by surgery as treatment for select patients with unresectable LASCC. Methods We studied patients with unresectable LASCC who received NACRT between November 2010 and April 2019. The NACRT regimen consisted of intensity modulated radiotherapy (IMRT) of 50 Gy to the gross tumor and positive lymphoma node and 45 Gy to the clinical target volume. Capecitabine‑based chemotherapy was administered every 2 (mFOLFOX6) or 3 weeks (CAPEOX). Surgery was scheduled 6–8 weeks after radiotherapy. Results Seventy‑two patients were enrolled in this study. Patients had a regular follow-up (median, 41.1 months; range, 8.3–116.5 months). Seventy‑one patients completed NACRT, and sixty-five completed surgery. Resection with microscopically negative margins (R0 resection) was achieved in 64 patients (88.9%). Pathologic complete response was observed in 15 patients (23.1%), and multivisceral resection was necessary in 38 patients (58.3%). The cumulative probability of 3-year overall survival (OS) and progression-free survival (PFS) were 75.8 and 70.7%, respectively. Conclusions For patients with unresectable LASCC, neoadjuvant chemoradiotherapy is feasible, surgery can be performed safely and may result in increased survival and organ preservation rates.
Databáze: OpenAIRE
Externí odkaz: